<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834977</url>
  </required_header>
  <id_info>
    <org_study_id>40012</org_study_id>
    <nct_id>NCT00834977</nct_id>
  </id_info>
  <brief_title>Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Conditions</brief_title>
  <official_title>Randomized, 2-Way, Crossover, Bioequivalence Study of Amlodipine-Benazepril 10mg-20mg Capsules and Lotrel® Administered as 1 x 10 mg-20 mg Capsule in Healthy Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of&#xD;
      amlodipine-benzazepril 10 mg-20 mg capsules (test) versus Lotrel® (reference), administered&#xD;
      as 1 x 10 mg capsule under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria&#xD;
&#xD;
      Statistical Methods: FDA bioequivalence statistical methods&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Amlodipine</measure>
    <time_frame>Blood samples collected over 168 hour period</time_frame>
    <description>Bioequivalence based on Cmax - Maximum observed concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf - Amlodipine</measure>
    <time_frame>Blood samples collected over 168 hour period</time_frame>
    <description>Bioequivalence based on AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Amlodipine</measure>
    <time_frame>Blood samples collected over 168 hour period</time_frame>
    <description>Bioequivalence based on AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax - Benazepril</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
    <description>Bioequvialence based on Cmax - Maximum observed concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf - Benazepril</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
    <description>Bioequivalence based on AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Benazepril</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
    <description>Bioequivalence based on AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax - Benazeprilat</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
    <description>Cmax - Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf - Benazeprilat</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
    <description>AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t - Benazaprilat</measure>
    <time_frame>Blood samples collected over 36 hour period</time_frame>
    <description>AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Amlodipine Benazepril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lotrel®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsules (test) dosed in second period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine-benazepril 10 mg-20 mg capsules</intervention_name>
    <description>1 x 10-20 mg</description>
    <arm_group_label>Amlodipine Benazepril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lotrel® 10 mg-20 mg capsule</intervention_name>
    <description>1 x 10-20 mg</description>
    <arm_group_label>Lotrel®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male of non-child-bearing potential female, non-smoker, 18 years of age and older.&#xD;
&#xD;
          -  Non-child-bearing potential female subjects is defined as follows:&#xD;
&#xD;
          -  Post-menopausal state: absence of menses for 12 months prior to drug administration or&#xD;
             hysterectomy woth bilateral oophorectomy at least 6 months prior to drug&#xD;
             administration.&#xD;
&#xD;
          -  Surgically sterile: hysterectomy, bilateral oophorectomy, or tubal ligation at least 6&#xD;
             months prior to drug administration.&#xD;
&#xD;
          -  Capable of consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant illnesses within 4 weeks prior to the administration of the&#xD;
             study medication.&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks prior to the administration of the study&#xD;
             medication&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          -  Abnormal laboratory tests judges clinically significant.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.&#xD;
&#xD;
          -  EGC abnormalities (clinically significant) or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 100 ot over 140 nnHg, diastolic blood pressure lower than 60 or&#xD;
             over 90 mmHg, or heart rate less that 60 or over 100 bpm) at screening.&#xD;
&#xD;
          -  BMI ≥ 30.0&#xD;
&#xD;
          -  History of significant alcohol abuse within six months prior to the screening visit or&#xD;
             any indication of the regular use of more than fourteen units of alcohol per week ( 1&#xD;
             Unit= 150 mL of wine, 360 mL of beer, or 45 mL ot 40% alcohol) or positive alcohol&#xD;
             breath test at screening.&#xD;
&#xD;
          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana)&#xD;
             within 3 months prior to the screening visit or hard drugs( such as cocaine,&#xD;
             phencyclidine [PCP] and crack) within 1 year prior to the screening visit or positive&#xD;
             urine drug screen at screening.&#xD;
&#xD;
          -  History of allergic reactions to heparin,amlodipine,benazepril, or other ACE&#xD;
             inhibitors, or other related drugs.&#xD;
&#xD;
          -  Use of any drugs known to induce hepatic drug metabolism (examples of inducers:&#xD;
             barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; examples of&#xD;
             inhibitors: antidepressant (SSRI), cimetidine, diltiazem, macrolides, imidazoles,&#xD;
             neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to&#xD;
             administration of the study medication.&#xD;
&#xD;
          -  Use of and investigational drug or participation in an investigational study within 30&#xD;
             days prior to administration of the study medication.&#xD;
&#xD;
          -  Clinically significant history or presence of any clinically significant&#xD;
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),&#xD;
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver of kidney&#xD;
             disease, or other conditions known to interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of the drug.&#xD;
&#xD;
          -  Any clinically significant history or presence of clinically significant neurological,&#xD;
             endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or&#xD;
             metabolic disease.&#xD;
&#xD;
          -  Use of prescription medication ( including hormone replacement therapy) within 14 days&#xD;
             prior to administration of study medication or over-the-counter products (including&#xD;
             natural food supplements, vitamins, garlic as a supplement) within 7 days prior to&#xD;
             administration of study medication, except for topical products without systemic&#xD;
             absorption.&#xD;
&#xD;
          -  Difficulty to swallow study medication. Subjects who have used tobacco in any form&#xD;
             within the 90 days preceding study drug administration&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             Medical Sub-Investigator, could contraindicate the subject's participation in this&#xD;
             study.&#xD;
&#xD;
          -  A depot injection or an implant of any drug within 3 months prior to administration of&#xD;
             study medication.&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 30 days prior to drug administration. Donation or&#xD;
             loss of whole blood (excluding the volume of blood that will be drawn during the&#xD;
             screening procedures of this study) prior to administration of the study medication as&#xD;
             follows:&#xD;
&#xD;
          -  50 mL to 300 mL of whole blood within 30 days,&#xD;
&#xD;
          -  301 mL to 500 mL of whole blood within 45 days, or&#xD;
&#xD;
          -  more than 500 mL of whole blood within 56 days prior to drug administration.&#xD;
&#xD;
          -  Consumption of food or beverages containing grapefruit ( e.g. fresh, canned, or&#xD;
             frozen) within 7 days prior to administration of the study medication.&#xD;
&#xD;
          -  Intolerance to venipunctures&#xD;
&#xD;
          -  Unable to understand or unwilling to sign the Informed Consent Form.&#xD;
&#xD;
          -  Clinically significant history of angioedema. Subjects with a clinically significant&#xD;
             history or active hypotension. Subjects with a significant history of active&#xD;
             neutropenia and/or agranulocytosis.&#xD;
&#xD;
          -  Breast-feeding subject.&#xD;
&#xD;
          -  Positive urine pregnancy test at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Larouche, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3X H29</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SFBC Anapharm</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>May 6, 2009</results_first_submitted>
  <results_first_submitted_qc>July 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2009</results_first_posted>
  <last_update_submitted>July 6, 2009</last_update_submitted>
  <last_update_submitted_qc>July 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Benazepril</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amlodipine Benazepril (Test) First</title>
          <description>Amlodipine Benazepril 10/20 mg capsule (test) dosed in first period followed by Lotrel® 10/20 mg capsule (reference) in second period</description>
        </group>
        <group group_id="P2">
          <title>Lotrel® (Reference) First</title>
          <description>Lotrel® 10/20 mg capsule (reference) dosed in first period followed by Amlodipine Benazepril 10/20 mg capsule (test) dosed in second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amlodipine Benazepril (Test) First</title>
          <description>Amlodipine Benazepril 10/20 mg capsule (test) dosed in first period followed by Lotrel® 10/20 mg capsule (reference) in second period</description>
        </group>
        <group group_id="B2">
          <title>Lotrel® (Reference) First</title>
          <description>Lotrel® 10/20 mg capsule (reference) dosed in first period followed by Amlodipine Benazepril 10/20 mg capsule (test) dosed in second period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Amlodipine</title>
        <description>Bioequivalence based on Cmax - Maximum observed concentration</description>
        <time_frame>Blood samples collected over 168 hour period</time_frame>
        <population>One subject was excluded from all statistical analysis for Amlodipine based on a pre-dose plasma concentration greater than 5% of the Cmax value.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Amlodipine</title>
          <description>Bioequivalence based on Cmax - Maximum observed concentration</description>
          <population>One subject was excluded from all statistical analysis for Amlodipine based on a pre-dose plasma concentration greater than 5% of the Cmax value.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6299.49" spread="1917.69"/>
                    <measurement group_id="O2" value="6185.06" spread="1697.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>101.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>97.23</ci_lower_limit>
            <ci_upper_limit>105.09</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf - Amlodipine</title>
        <description>Bioequivalence based on AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
        <time_frame>Blood samples collected over 168 hour period</time_frame>
        <population>One subject was excluded from all statistical analysis for Amlodipine based on a pre-dose plasma concentration greater than 5% of the Cmax value.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - Amlodipine</title>
          <description>Bioequivalence based on AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
          <population>One subject was excluded from all statistical analysis for Amlodipine based on a pre-dose plasma concentration greater than 5% of the Cmax value.</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365612.90" spread="143713.73"/>
                    <measurement group_id="O2" value="366523.24" spread="140268.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>99.38</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>96.63</ci_lower_limit>
            <ci_upper_limit>102.22</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Amlodipine</title>
        <description>Bioequivalence based on AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
        <time_frame>Blood samples collected over 168 hour period</time_frame>
        <population>One subject was excluded from all statistical analysis for Amlodipine based on a pre-dose plasma concentration greater than 5% of the Cmax value.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Amlodipine</title>
          <description>Bioequivalence based on AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
          <population>One subject was excluded from all statistical analysis for Amlodipine based on a pre-dose plasma concentration greater than 5% of the Cmax value.</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328249.86" spread="118686.43"/>
                    <measurement group_id="O2" value="331782.17" spread="114025.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>98.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>95.80</ci_lower_limit>
            <ci_upper_limit>101.23</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Benazepril</title>
        <description>Bioequvialence based on Cmax - Maximum observed concentration</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Benazepril</title>
          <description>Bioequvialence based on Cmax - Maximum observed concentration</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330.93" spread="162.44"/>
                    <measurement group_id="O2" value="340.57" spread="163.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>98.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>86.95</ci_lower_limit>
            <ci_upper_limit>112.09</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax - Benazeprilat</title>
        <description>Cmax - Maximum observed concentration</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Benazeprilat</title>
          <description>Cmax - Maximum observed concentration</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378.27" spread="117.87"/>
                    <measurement group_id="O2" value="397.50" spread="126.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>95.69</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>90.54</ci_lower_limit>
            <ci_upper_limit>101.14</ci_upper_limit>
            <estimate_desc>Metabolite presented for informational purposes only.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf - Benazeprilat</title>
        <description>AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - Benazeprilat</title>
          <description>AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2027.53" spread="559.69"/>
                    <measurement group_id="O2" value="2033.12" spread="508.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Slope</param_type>
            <param_value>99.43</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>96.48</ci_lower_limit>
            <ci_upper_limit>102.46</ci_upper_limit>
            <estimate_desc>Metabolite presented for informational purposes only.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf - Benazepril</title>
        <description>Bioequivalence based on AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - Benazepril</title>
          <description>Bioequivalence based on AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245.15" spread="113.78"/>
                    <measurement group_id="O2" value="253.21" spread="125.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>97.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.82</ci_lower_limit>
            <ci_upper_limit>101.78</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Benazepril</title>
        <description>Bioequivalence based on AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Benazepril</title>
          <description>Bioequivalence based on AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.65" spread="113.50"/>
                    <measurement group_id="O2" value="250.13" spread="125.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>96.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.52</ci_lower_limit>
            <ci_upper_limit>101.68</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t - Benazaprilat</title>
        <description>AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
        <time_frame>Blood samples collected over 36 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine Benazepril</title>
            <description>Amlodipine Benazepril 10/20 mg capsule (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Lotrel®</title>
            <description>Lotrel® 10/20 mg capsule (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Benazaprilat</title>
          <description>AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1981.29" spread="556.26"/>
                    <measurement group_id="O2" value="1990.26" spread="506.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Parametric analysis of variance (ANOVA)on AUC0-t, AUCinf and Cmax; geometric Confidence Intervals for AUC0-t, AUC0-inf and Cmax</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>99.24</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>96.21</ci_lower_limit>
            <ci_upper_limit>102.35</ci_upper_limit>
            <estimate_desc>Metabolite presented for informational purposes only.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>TEVA Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

